
Quarterly report 2025-Q3
added 11-12-2025
Electromed Revenue 2011-2026 | ELMD
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Electromed
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64 M | 54.7 M | 48.1 M | 41.7 M | 35.8 M | 32.5 M | 31.3 M | 28.7 M | 25.9 M | 23 M | 19.4 M | 15.5 M | 15.1 M | 19.5 M | 19 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 64 M | 15.1 M | 31.6 M |
Quarterly Revenue Electromed
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 16.9 M | - | 15.7 M | 16.3 M | 14.7 M | - | 13.9 M | 13.7 M | 12.3 M | - | 12.1 M | 11.7 M | 10.7 M | 22.4 M | 10.1 M | 10.2 M | 10 M | 20.2 M | 8.79 M | 9.5 M | 8 M | 9.5 M | 8 M | 8.55 M | 8.3 M | 8.55 M | 8.3 M | 8.01 M | 7.28 M | 8.01 M | 7.28 M | 6.96 M | 6.3 M | 6.98 M | 6.38 M | 6.37 M | 5.55 M | 6.37 M | 5.55 M | 6.26 M | 5 M | 6.26 M | 5 M | 4.88 M | 4.77 M | 4.88 M | 4.77 M | 3.5 M | 3.42 M | 3.5 M | 3.42 M | 3.86 M | 4.03 M | 3.86 M | 4.03 M | 4.79 M | 5.38 M | 4.79 M | 5.38 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 22.4 M | 3.42 M | 8.24 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
AxoGen
AXGN
|
187 M | $ 34.1 | 3.49 % | $ 1.51 B | ||
|
Abiomed
ABMD
|
848 M | - | - | $ 17.2 B | ||
|
Boston Scientific Corporation
BSX
|
16.7 B | $ 100.0 | 1.37 % | $ 147 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
612 M | $ 23.09 | 5.1 % | $ 3.3 B | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.43 | -0.87 % | $ 119 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 9.52 | -0.23 % | $ 684 M | ||
|
Bio-Rad Laboratories
BIO
|
2.57 B | $ 318.95 | -1.6 % | $ 9 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 52.28 | -1.38 % | $ 7.79 K | ||
|
CONMED Corporation
CNMD
|
1.31 B | $ 44.18 | 1.75 % | $ 1.36 B | ||
|
Abbott Laboratories
ABT
|
42 B | $ 127.39 | 0.28 % | $ 222 B | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.72 | -2.11 % | $ 139 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
GBS
GBS
|
3.05 M | - | -0.57 % | $ 7.12 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 14.63 | -6.49 % | $ 1.16 B | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 99.06 | 0.73 % | $ 1.26 B | ||
|
IRIDEX Corporation
IRIX
|
51.9 M | $ 1.18 | -0.84 % | $ 19 M | ||
|
Align Technology
ALGN
|
4 B | $ 170.76 | 2.37 % | $ 12.8 B | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 0.89 | 1.99 % | $ 91.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
205 M | $ 18.89 | 2.72 % | $ 436 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
31.4 M | $ 15.41 | 0.78 % | $ 416 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.54 | - | $ 122 M | ||
|
LENSAR
LNSR
|
53.5 M | $ 11.81 | 2.43 % | $ 136 M | ||
|
Globus Medical
GMED
|
2.52 B | $ 95.52 | 5.51 % | $ 13 B | ||
|
LivaNova PLC
LIVN
|
1.25 B | $ 65.28 | 1.02 % | $ 3.54 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 13.38 | 1.75 % | $ 1.03 B | ||
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Establishment Labs Holdings
ESTA
|
166 M | $ 71.53 | 2.16 % | $ 2.01 B |